About FDA
Percent of advisory committee members participating in meetings in the month who were granted waivers
FY 2010 Target: Less than 13.04%
Dictionary: When FDA determines that an advisory committee member has a financial conflict of interest, the agency may grant a waiver that allows the member to participate in an advisory committee meeting if certain criteria and policies are met. In general, FDA may grant a waiver if the member's expertise is considered essential to the committee’s discussions and recommendations. FDA must also take into consideration a cap on the number of waivers that can be granted each year. FDA searches for experts who have the necessary expertise without conflicts of interest; yet, in some cases, many of the top authorities in specialized scientific fields may have a conflict of interest. When FDA grants a waiver, the financial interests associated with the waiver are posted on FDA’s website along with the reasons for granting the waiver.
Information is current as of December 31, 2012.
Fiscal Year - 2010
FY 2010 Target: Less than 13.04%
| Time | Target | Percent Granted Waivers |
|---|---|---|
| Oct 2009 | 13.04 | 4 |
| Nov 2009 | 13.04 | 2 |
| Dec 2009 | 13.04 | 1 |
| Jan 2010 | 13.04 | 0 |
| Feb 2010 | 13.04 | 0 |
| Mar 2010 | 13.04 | 2 |
| Apr 2010 | 13.04 | 0 |
| May 2010 | 13.04 | 1 |
| Jun 2010 | 13.04 | 0 |
| Jul 2010 | 13.04 | 1 |
| Aug 2010 | 13.04 | 0 |
| Sep 2010 | 13.04 | 0 |
FY 2010 Overall: 1%
Total number of advisory committee members participating in meetings in the month who were granted waivers
Fiscal Year - 2010
| Time | Target | Waivers Granted |
|---|---|---|
| Oct 2009 | N/A | 4 |
| Nov 2009 | N/A | 3 |
| Dec 2009 | N/A | 1 |
| Jan 2010 | N/A | 0 |
| Feb 2010 | N/A | 0 |
| Mar 2010 | N/A | 4 |
| Apr 2010 | N/A | 0 |
| May 2010 | N/A | 1 |
| Jun 2010 | N/A | 0 |
| Jul 2010 | N/A | 1 |
| Aug 2010 | N/A | 0 |
| Sep 2010 | N/A | 0 |
FY 2010 Total: 14
Total number of advisory committee members participating in meetings in the month
Fiscal Year - 2010
| Time | Target | Committee Members |
|---|---|---|
| Oct 2009 | N/A | 111 |
| Nov 2009 | N/A | 131 |
| Dec 2009 | N/A | 192 |
| Jan 2010 | N/A | 32 |
| Feb 2010 | N/A | 55 |
| Mar 2010 | N/A | 190 |
| Apr 2010 | N/A | 96 |
| May 2010 | N/A | 94 |
| Jun 2010 | N/A | 81 |
| Jul 2010 | N/A | 163 |
| Aug 2010 | N/A | 63 |
| Sep 2010 | N/A | 115 |
FY 2010 Total: 1,323
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.







